In vitro the behaviors of metastasis with suppression of VEGF in human bone metastatic LNCaP-derivative C4-2B prostate cancer cell line.

Lei Yang,Chaoyue Zhang,Ya Cao,Shuo You,Vikas Kumar

doi:10.1186/1756-9966-31-40

Abstract

BackgroundVascular endothelial growth factor (VEGF) is a signal protein produced by cells that stimulates vasculogenesis and angiogenesis. VEGF is believed to implicate poor prognosis in various cancers. The overexpression of VEGF may be an early step in the process of metastasis.MethodsELISA was used to investigate the levels of VEGF, bFGF and IL8 in human bone metastatic LNCaP-derivative C4-2B prostate cancer cell line and its parental cell line, LNCaP and to determine the effect of bevacizumab on reducing the level of VEGF. Cell proliferation assay, invasion assay and in vitro angiogenesis assay were performed under the condition with bevacizumab or control IgG.ResultsHuman bone metastatic LNCaP-derivative C4-2B prostate cancer cell line expressed a higher level of VEGF than its parental primary prostate cancer cell line LNCaP. The effect of bevacizumab is dose-dependent and time-dependent: 100 μg/mL of bevacizumab and 3-day treatment was more effective than low-dose and lesser-day treatment for decreasing the level of VEGF. Bevacizumab is able to suppress cell proliferation, angiogenesis and invasion in human bone metastatic C4-2B prostatic cancer cell line.ConclusionsThe overexpression of VEGF can be inhibited by bevacizumab in human bone metastatic cancer cell line. The behaviors of metastasis involving proliferation, angiogenesis and invasion are suppressed by anti-VEGF therapy.

Highlights

Vascular endothelial growth factor (VEGF) is a signal protein produced by cells that stimulates vasculogenesis and angiogenesis
Expression of VEGF, basic fibroblast growth factor (bFGF) and interleukin 8 (IL-8) To screen for the expression of angiogenic factors in prostate cancer cell and its bone metastatic cell, three angiogenic factors in conditioned media were detected with enzyme-linked immunosorbent assay (ELISA)
Bevacizumab suppressed VEGF from C4-2B and microvessel cells To determine the concentration of bevacizumab needed for neutralizing the secreted VEGF by bone metastatic treatment cells and control IgG treatment cells (P < 0.01, Figure 1)

Summary

Introduction

Vascular endothelial growth factor (VEGF) is a signal protein produced by cells that stimulates vasculogenesis and angiogenesis. VEGF is believed to implicate poor prognosis in various cancers. The overexpression of VEGF may be an early step in the process of metastasis. It is much less common to have a primary bone cancer that arises from cells that make up the bone. Chemotherapy and radiation therapy are the three main types of treatment for bone cancer. There are risks and side effects associated with each of the treatments for bone cancer. The main risks associated with surgery include infection, recurrence of the cancer, and injury to the surrounding tissues that may cause loss of sensation, strength or function, or even cause amputation.

Objectives

Methods

Results

Discussion

Conclusion